期刊
FRONTIERS IN MOLECULAR BIOSCIENCES
卷 8, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fmolb.2021.716415
关键词
annexin A3; biomarkers; drug resistance; neoplasm; signal transduction; tumorigenesis
资金
- Development and Promotion Project of Guangxi Medical and Health Appropriate Technology [S2018038]
- Key Laboratory of High-Incidence-Tumor Prevention and Treatment (Guangxi Medical University) [GK 2018-08, GKE-ZZ202012]
- General Program of Guangxi Natural Science Foundation [2018GXNSFAA281032]
ANXA3 is dysregulated in various malignancies and contributes to tumor development as well as resistance to chemotherapy. Genetic alterations on the ANXA3 gene are associated with certain familial tumors. Thus, ANXA3 may serve as an important target for anticancer therapies and early tumor detection.
Annexin A3 (ANXA3), also known as lipocortin III and placental anticoagulant protein III, has been reported to be dysregulated in tumor tissues and cancer cell lines, and harbors pronounced diagnostic and prognostic value for certain malignancies, such as breast, prostate, colorectal, lung and liver cancer. Aberrant expression of ANXA3 promotes tumor cell proliferation, invasion, metastasis, angiogenesis, and therapy resistance to multiple chemotherapeutic drugs including platinum-based agents, fluoropyrimidines, cyclophosphamide, doxorubicin, and docetaxel. Genetic alterations on the ANXA3 gene have also been reported to be associated with the propensity to form certain inherited, familial tumors. These diverse functions of ANXA3 in tumors collectively indicate that ANXA3 may serve as an attractive target for novel anticancer therapies and a powerful diagnostic and prognostic biomarker for early tumor detection and population risk screening. In this review, we dissect the role of ANXA3 in cancer in detail.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据